ARK Genomic Revolution ETF Target of Unusually High Options Trading (BATS:ARKG)

ARK Genomic Revolution ETF (BATS:ARKG) saw unusually large options trading activity on Wednesday. Stock investors acquired 79,250 put options on the stock. This is an increase of approximately 700% compared to the average volume of 9,906 put options.

ARK Genomic Revolution ETF Trading Down 2.2 %

ARKG traded down $0.57 during midday trading on Wednesday, hitting $25.59. The company had a trading volume of 4,817,059 shares. The stock’s 50 day simple moving average is $24.75 and its 200 day simple moving average is $24.99.

Institutional Trading of ARK Genomic Revolution ETF

A number of hedge funds have recently bought and sold shares of the business. Prudential PLC increased its holdings in shares of ARK Genomic Revolution ETF by 15.0% in the second quarter. Prudential PLC now owns 140,170 shares of the company’s stock worth $3,326,000 after purchasing an additional 18,300 shares during the period. Choreo LLC purchased a new stake in shares of ARK Genomic Revolution ETF in the 2nd quarter valued at $314,000. Headlands Technologies LLC boosted its position in ARK Genomic Revolution ETF by 5,878.2% during the second quarter. Headlands Technologies LLC now owns 21,163 shares of the company’s stock valued at $497,000 after buying an additional 20,809 shares during the period. Mercer Global Advisors Inc. ADV boosted its holdings in ARK Genomic Revolution ETF by 901.5% during the 2nd quarter. Mercer Global Advisors Inc. ADV now owns 28,943 shares of the company’s stock valued at $680,000 after acquiring an additional 26,053 shares during the period. Finally, Bridges Investment Management Inc. increased its stake in shares of ARK Genomic Revolution ETF by 3.8% in the second quarter. Bridges Investment Management Inc. now owns 14,121 shares of the company’s stock worth $332,000 after buying an additional 517 shares during the period.

About ARK Genomic Revolution ETF

The ARK Genomic Revolution ETF (ARKG) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund is an actively managed fund that targets companies involved in the genomics industry. ARKG was launched on Oct 31, 2014 and is managed by ARK.